miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

DevvStream, Southern, and Frontline BioEnergy to Advance Biomass-to-Jet Development and Environmental-Asset Monetization

View original at finance.yahoo.com
DevvStream, Southern, and Frontline BioEnergy to Advance Biomass-to-Jet Development and Environmental-Asset Monetization SACRAMENTO, Calif., January 28, 2026--(BUSINESS WIRE)--DevvStream Corp…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If the three parties are able to successfully negotiate definitive agreements, DevvStream believes the Frontline pilot-scale program can help validate Southern's biomass-to-methanol and methanol-to-jet pathways, complement XCF's downstream SAF production capabilities, and further de-risk commercialization for the proposed Louisiana development pathway

    80% confidence
  • Frontline was built to solve the hard part of biomass and waste conversion, delivering clean syngas that enables high-value fuels and chemicals. The company is excited about expanding demonstration capabilities with methanol production and methanol-to-hydrocarbons conversion to produce data and operational confidence needed for commercial deployment

    80% confidence
  • This term sheet advances a practical de-risking plan to generate real operating data, validate feedstocks and yields, and move toward definitive commercial agreements with a proven technology partner. Frontline's platform and experience, combined with a structured validation program and environmental-attribute strategy, is intended to strengthen execution profile for the proposed Louisiana development pathway

    80% confidence
  • This collaboration is designed to convert innovation into bankable execution. By pairing Frontline's demonstrated gasification and gas-cleanup capabilities with demonstration-scale methanol and methanol-to-jet validation, Southern is building a more disciplined pathway to de-risk engineering, strengthen project economics, and support a credible commercialization timeline

    80% confidence
  • For DevvStream shareholders, the exclusive role in the environmental-asset layer is intended to create an additional, scalable value stream tied to project performance and market demand

    80% confidence

Data points we hold from this source

NASDAQ · minimum bid price1.00 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com